Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 34NETWORK 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 3Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 62Vincristine 45Doxorubicin 43Etoposide 42Rituximab 37Prednisone 31Filgrastim 31Biopsy 27Peripheral Blood Stem Cell Transplantation 25Cytarabine 24Radiotherapy 22fludarabine phosphate 19Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 18Prednisolone 17Melphalan 16Ifosfamide 14Dexamethasone 14Bleomycin 13Leucovorin 12Cyclosporine 12Carmustine 12sargramostim 11Cisplatin 10Vinblastine 8Chlorambucil 8Busulfan 8fludarabine 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma × ibritumomab tiuxetan × Clear all
NCT00070447 2014-01-28

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡